FIRST MANHATTAN CO. LLC. - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 126 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.

Quarter-by-quarter ownership
FIRST MANHATTAN CO. LLC. ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$000.00%
Q2 2023$000.00%
Q1 2023$000.00%
Q4 2022$000.00%
Q3 2022$000.00%
Q2 2022$000.00%
Q1 2022$000.00%
Q4 2021$000.00%
Q3 2021$000.00%
Q2 2021$000.00%
Q1 2021$000.00%
Q4 2020$000.00%
Q3 2020$000.00%
Q2 2020$000.00%
Q3 2018$0
-100.0%
0
-100.0%
0.00%
-100.0%
Q2 2018$14,040,000
-9.6%
619,085
-3.3%
0.08%
-8.0%
Q1 2018$15,528,000
-61.7%
640,355
-56.0%
0.09%
-60.4%
Q4 2017$40,556,000
-26.6%
1,454,167
-9.9%
0.22%
-29.7%
Q3 2017$55,234,000
-21.0%
1,613,167
-8.1%
0.32%
-22.5%
Q2 2017$69,903,000
+3.4%
1,754,600
-4.4%
0.41%
+1.5%
Q1 2017$67,600,000
+15.2%
1,835,984
-0.3%
0.40%
+12.6%
Q4 2016$58,705,000
+55.2%
1,841,455
+76.4%
0.36%
+54.5%
Q3 2016$37,824,000
+63.2%
1,043,733
+2.2%
0.23%
+62.7%
Q2 2016$23,171,000
+21.4%
1,021,233
+0.6%
0.14%
+21.4%
Q1 2016$19,092,000
+10.2%
1,015,541
-3.9%
0.12%
+10.4%
Q4 2015$17,329,000
+35.9%
1,057,292
-8.9%
0.11%
+29.3%
Q3 2015$12,751,000
-16.5%
1,160,295
-1.0%
0.08%
-8.9%
Q2 2015$15,267,000
-32.3%
1,172,589
-9.7%
0.09%
-30.8%
Q1 2015$22,536,000
+4.4%
1,298,947
-10.2%
0.13%
+6.6%
Q4 2014$21,588,000
-23.4%
1,446,960
+18.3%
0.12%
-25.6%
Q3 2014$28,182,000
+194.0%
1,222,665
+306.6%
0.16%
+168.9%
Q2 2014$9,587,000300,7320.06%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2021
NameSharesValueWeighting ↓
Link Fund Solutions Ltd 5,251,349$135,459,00069.86%
Chescapmanager LLC 949,006$24,570,0003.61%
Baupost Group 9,309,168$241,014,0002.66%
Rock Springs Capital Management LP 655,200$16,963,0000.54%
Rubric Capital Management LP 173,400$4,489,0000.51%
Newtyn Management, LLC 173,300$4,487,0000.41%
NJ State Employees Deferred Compensation Plan 38,142$988,0000.17%
King Wealth Management Group 22,500$583,0000.15%
Virtus ETF Advisers LLC 29,216$756,0000.12%
JACOBS LEVY EQUITY MANAGEMENT, INC 452,615$11,718,0000.12%
View complete list of THERAVANCE BIOPHARMA INC shareholders